Home LiteratureArticle Details
PMID: 18431501 Published · epublish English

BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history.

PloS one ·Vol. 3 ·No. 4 ·2008-05-28

Toh Gaik Theng, Kang Peter, Lee Sharlene S W, Lee Daphne Shin-Chi, Lee Sheau Yee, Selamat Suhaida, Mohd Taib Nur Aishah, Yoon Sook-Yee, Yip Cheng Har, Teo Soo-Hwang

Abstract

In Asia, breast cancer is characterised by an early age of onset: In Malaysia, approximately 50% of cases occur in women under the age of 50 years. A proportion of these cases may be attributable, at least in part, to genetic components, but to date, the contribution of genetic components to breast cancer in many of Malaysia's ethnic groups has not been well-characterised.,Given that hereditary breast carcinoma is primarily due to germline mutations in one of two breast cancer susceptibility genes, BRCA1 and BRCA2, we have characterised the spectrum of BRCA mutations in a cohort of 37 individuals with early-onset disease (<or=40 years) and no reported family history. Mutational analysis of BRCA1 and BRCA2 was conducted by full sequencing of all exons and intron-exon junctions.,Here, we report a total of 14 BRCA1 and 17 BRCA2 sequence alterations, of which eight are novel (3 BRCA1 and 5 BRCA2). One deleterious BRCA1 mutation and 2 deleterious BRCA2 mutations, all of which are novel mutations, were identified in 3 of 37 individuals. This represents a prevalence of 2.7% and 5.4% respectively, which is consistent with other studies in other Asian ethnic groups (4-9%).

Article Info
Journal
PloS one
Abbr.
PLoS One
Published
2008-05-28
Indexed
2008-04-23
Updated
2014-09-03
Language
English
Country/Region
United States
NLM ID
101285081
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com